Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: A randomized, open-label, ascending single- and multiple-dose study

Clinical Therapeutics

Volumn 32, Issue 3, 2010, Pages 575-587

  Li, Xue Ning ^a   Xu, Hong Rong ^a   Chen, Wei Li ^a   Chu, Nan Nan ^a   Zhu, Jun Ren ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

LC MS MS; N desmethyl rosuvastatin; Pharmacokinetics; Rosuvastatin; Rosuvastatin lactone

Indexed keywords

CREATINE KINASE; DRUG METABOLITE; N DESMETHYLROSUVASTATIN; ROSUVASTATIN; ROSUVASTATIN LACTONE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CHINA; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATINE KINASE BLOOD LEVEL; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG FEVER; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HUMAN; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SPRAIN; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TINNITUS; VOLUNTEER;

ADMINISTRATION, ORAL; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LACTONES; MALE; PYRIMIDINES; SULFONAMIDES; TABLETS; YOUNG ADULT;

EID: 77951927236     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.03.015     Document Type: Article

References (17)

1. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001, 87:28B-32B.
2. Martin PD, Mitchell PD, Schneck DW Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol. 2002, 54:472-477.
3. McKenney JM Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am J Health Syst Pharm. 2005, 62:1033-1047.
4. Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther. 2003, 25:2822-2835.
5. Martin PD, Warwick MJ, Dane AL, et al. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther. 2003, 25:2553-2563.
6. Olsson AG, Pears J, McKellar J, et al. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol. 2001, 88:504-508.
7. Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 2002, 89:268-275.
8. Warwick MJ, Dane AL, Raza A, Schneck DW Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522. Atherosclerosis 2000, 151:39. Abstract.
9. Sekino H, Onishi T Phase I study of ZD4522 (rosuvastatin), a new HMG-CoA reductase inhibitor-evaluation of tolerance and pharmacokinetics in healthy adult male volunteers after single and repeated oral administration. J Clin Ther Med. 2005, 21:187-203.
10. Tzeng TB, Schneck DW, Birmingham BK, et al. Population pharmacokinetics of rosuvastatin: Implications of renal impairment, race, and dyslipidaemia. Curr Med Res Opin. 2008, 24:2575-2585.
11. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharma-cokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005, 78:330-341.
12. Li Y, Jiang X, Lan K, et al. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: A randomized, open-label, three-way crossover study. Clin Ther. 2007, 29:2194-2203.
13. Martin PD, Warwick MJ, Dane AL, Cantarini MV A doubleblind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin Ther. 2003, 25:2215-2224.
14. CPMP/ICH/135/95 July 2002, European Medicines Agency (EMEA) Guideline for Good Clinical Practice ICH Topic E 6 (R1), Accessed October 28, 2009. http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf.
15. World Medical Association Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects Accessed October 28, 2009. http://www.wma.net/en/30publications/10policies/b3/index.html.
16. Technical guidance for pharmacokinetic studies of chemical drugs State Food and Drug Administration of China, Accessed February 23, 2010. http://www.sfda.gov.cn/WS01/CL0055/10368.html.
17. Gough LL, Pratt BA, Rumsey SC, et al. Quality control and quality assurance: Two sides of the same coin. Qual Assur. 1995, 4:348-350.